JP2020531511A - 眼球用医薬組成物 - Google Patents

眼球用医薬組成物 Download PDF

Info

Publication number
JP2020531511A
JP2020531511A JP2020511176A JP2020511176A JP2020531511A JP 2020531511 A JP2020531511 A JP 2020531511A JP 2020511176 A JP2020511176 A JP 2020511176A JP 2020511176 A JP2020511176 A JP 2020511176A JP 2020531511 A JP2020531511 A JP 2020531511A
Authority
JP
Japan
Prior art keywords
compound
active agent
pharmaceutically acceptable
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531511A5 (https=
Inventor
バークマン，アラン
レビン，マーク・エイチ
Original Assignee
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア filed Critical ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア
Publication of JP2020531511A publication Critical patent/JP2020531511A/ja
Publication of JP2020531511A5 publication Critical patent/JP2020531511A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020511176A 2017-08-24 2018-08-24 眼球用医薬組成物 Pending JP2020531511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549872P 2017-08-24 2017-08-24
US62/549,872 2017-08-24
PCT/US2018/048025 WO2019040919A1 (en) 2017-08-24 2018-08-24 OCULAR PHARMACEUTICAL COMPOSITIONS

Publications (2)

Publication Number Publication Date
JP2020531511A true JP2020531511A (ja) 2020-11-05
JP2020531511A5 JP2020531511A5 (https=) 2021-09-30

Family

ID=65439930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511176A Pending JP2020531511A (ja) 2017-08-24 2018-08-24 眼球用医薬組成物

Country Status (8)

Country Link
US (3) US11839616B2 (https=)
EP (1) EP3672598A4 (https=)
JP (1) JP2020531511A (https=)
KR (1) KR20200044873A (https=)
CN (1) CN111629730A (https=)
AU (1) AU2018321926B2 (https=)
CA (1) CA3073718A1 (https=)
WO (1) WO2019040919A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023541261A (ja) * 2020-09-10 2023-09-29 バンダ・ファーマシューティカルズ・インコーポレイテッド Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
US12065412B2 (en) 2015-12-24 2024-08-20 The Regents Of The University Of California CFTR regulators and methods of use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957413B2 (en) * 2019-08-06 2024-04-16 University of Pittsburgh—of the Commonwealth System of Higher Education Solitary wave-based trans-lid tonometer
CN115397392A (zh) * 2019-12-05 2022-11-25 Vanda制药公司 眼用药物组合物
WO2025179141A1 (en) * 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPS62126178A (ja) 1985-11-26 1987-06-08 Mitsubishi Petrochem Co Ltd 新規トリアジン誘導体及びこれを含む除草剤
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
AU5433594A (en) 1992-11-19 1994-06-08 Dainippon Pharmaceutical Co. Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
WO1999038497A2 (en) 1998-01-30 1999-08-05 R-Tech Ueno, Ltd. Ophthalmic composition
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
CA2319554C (en) 1998-03-31 2005-06-28 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
CA2394727A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
RS34004A (sr) 2001-09-21 2006-10-27 Reddy Us Therapeutics Inc. Postupci i sastavi novih triazin jedinjenja
AU2003272740A1 (en) 2002-10-01 2004-04-23 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
AU2004259346A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
BRPI0507278A (pt) 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007095812A1 (en) 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
EP2037924A2 (en) 2006-07-07 2009-03-25 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
US8263607B2 (en) 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
US20120009151A1 (en) 2007-12-21 2012-01-12 Progenics Pharmaceuticals, Inc. Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof
HUE027811T2 (en) 2008-03-05 2016-11-28 Merck Patent Gmbh Quinoxalinone derivatives as stimulators of insulin secretion, methods for their preparation and their use in the treatment of diabetes
WO2010048564A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
FR2958645B1 (fr) 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US8883793B2 (en) 2010-12-29 2014-11-11 Development Center For Biotechnology Tubulin inhibitors and methods of using the same
AU2013365827A1 (en) 2012-12-19 2015-07-09 Novartis Ag Tricyclic compounds as CFTR inhibitors
PT3030568T (pt) 2013-08-08 2018-12-24 Galapagos Nv Tieno[2,3-c]piranos como moduladores de cftr
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP3347912A1 (de) 2015-09-11 2018-07-18 ION-TOF Technologies GmbH Sekundärionen-massenspektrometer und sekundärionen-massenspektrometrisches verfahren
US10035962B2 (en) * 2015-12-21 2018-07-31 Exxonmobil Research And Engineering Company Trim dewaxing of distillate fuel
BR112018012934B1 (pt) 2015-12-24 2023-11-07 The Regents Of The University Of California Reguladores cftr e métodos de uso dos mesmos
RU2742934C2 (ru) 2015-12-24 2021-02-11 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
AU2016379444B2 (en) 2015-12-24 2021-04-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
PL3722291T3 (pl) 2015-12-24 2023-11-27 Respivert Limited Związki indolinonowe i ich zastosowanie w leczeniu chorób zwłóknieniowych
JP2020531511A (ja) 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"点眼薬", 慶應義塾大学病院ホームページ, JPN6023012383, May 2017 (2017-05-01), ISSN: 0005027640 *
AMER. J. VET. RES., vol. 71, no. 6, JPN6023012381, 2010, pages 671 - 676, ISSN: 0005027638 *
INVEST. OPHTHAL. VIS. SCI., vol. 50, no. 5, JPN6022025178, 2009, pages 2132 - 2138, ISSN: 0005027637 *
J. MED. CHEM., vol. 60, JPN6022025177, January 2017 (2017-01-01), pages 1210 - 1218, ISSN: 0005027636 *
OCUL. SURF., vol. 14, no. 2, JPN6023012384, 2016, pages 264 - 316, ISSN: 0005027641 *
比較眼科雑誌, vol. 32, JPN6023012382, 2013, pages 3 - 13, ISSN: 0005027639 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12065412B2 (en) 2015-12-24 2024-08-20 The Regents Of The University Of California CFTR regulators and methods of use thereof
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
JP2023541261A (ja) * 2020-09-10 2023-09-29 バンダ・ファーマシューティカルズ・インコーポレイテッド Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法
JP7826294B2 (ja) 2020-09-10 2026-03-09 バンダ・ファーマシューティカルズ・インコーポレイテッド Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法

Also Published As

Publication number Publication date
AU2018321926B2 (en) 2023-09-21
EP3672598A4 (en) 2021-04-28
US20210154201A1 (en) 2021-05-27
AU2018321926A1 (en) 2020-03-12
RU2020111560A (ru) 2021-09-24
RU2020111560A3 (https=) 2021-10-29
US11839616B2 (en) 2023-12-12
US20240156828A1 (en) 2024-05-16
WO2019040919A1 (en) 2019-02-28
KR20200044873A (ko) 2020-04-29
EP3672598A1 (en) 2020-07-01
CA3073718A1 (en) 2019-02-28
CN111629730A (zh) 2020-09-04
US20250367207A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
US20250367207A1 (en) Ocular pharmaceutical compositions
ES2972099T3 (es) Formulación oftálmica
RU2470635C2 (ru) Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
KR101154175B1 (ko) 각결막 장해 치료제
US11192869B2 (en) CFTR regulators and methods of use thereof
US12370209B2 (en) Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
JP6480640B2 (ja) イマチニブを有効成分として含む眼球乾燥疾患予防及び治療用薬学組成物
EA024042B1 (ru) Способ снижения внутриглазного давления у людей
JP2019505502A (ja) Ｃｆｔｒ制御因子及びこの使用方法
US20190231765A1 (en) Methods for treating ocular disease using inhibitors of csf-1r
JP2000507205A (ja) 眼の虚血障害の治療薬の製造のためのポリアミン部位拮抗物質の使用
RU2818087C2 (ru) Офтальмологические фармацевтические композиции
US20090082455A1 (en) Therapeutic agent for ophthalmic disease
RU2423127C2 (ru) Терапевтическое средство против роговично-конъюнктивального нарушения
JP4456269B2 (ja) 視神経乳頭循環改善剤
CA3014071C (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
JP2002356431A (ja) ステロイドを有効成分とする網脈絡膜疾患治療剤
KR960013437B1 (ko) 산화형 글루타티온 점안제
WO2005108396A1 (ja) 角結膜障害治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230404